Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.44 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18794996 | 0.84 | GRM2 (0.53) | HSD17B10L3MBTL1POLBLMNAMAPT | |
| SCHEMBL949903 | 0.84 | HSD17B10 (0.61) | HSD17B10L3MBTL1POLBTDP1ALKBH1 | |
| SCHEMBL18795048 | 0.82 | GRM2 (0.55) | HSD17B10POLBLMNAMAPTKLKB1 | |
| SCHEMBL1912400 | 0.82 | HSD17B10 (0.77) | HSD17B10L3MBTL1POLBTDP1LMNA | |
| SCHEMBL19299982 | 0.80 | HSD17B10 (0.65) | HSD17B10L3MBTL1POLBTDP1EGLN1 | |
| SCHEMBL30755248 | 0.80 | HSD17B10 (0.57) | HSD17B10L3MBTL1POLBTDP1ALKBH1 | |
| SCHEMBL15520388 | 0.80 | HSD17B10 (0.57) | HSD17B10L3MBTL1POLBTDP1ALKBH1 | |
| SCHEMBL21316081 | 0.80 | EGLN1 (0.37) | HSD17B10L3MBTL1POLBTDP1EGLN1 | |
| SCHEMBL18816489 | 0.79 | HSD17B10 (0.63) | HSD17B10L3MBTL1POLBTDP1EGLN1 | |
| SCHEMBL553971 | 0.79 | HSD17B10 (0.63) | HSD17B10L3MBTL1POLBTDP1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368529-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3368529-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3368524-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3368524-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| US-10399961-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-09-03 | — | — | US | disclosed |
| US-10399961-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-09-03 | — | — | US | disclosed |
| WO-2017072021-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017072021-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017072020-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017072020-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-04 | — | — | WO | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8916591-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2014-12-23 | — | — | US | disclosed |
| EP-2294065-B1 | INDOLYL-PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS R&D LTD (GB) | 2014-03-19 | — | — | EP | disclosed |
| CN-101970424-B | Indolylpyridone derivatives with checkpoint kinase 1 inhibitory activity | VERNALIS R&D LTD | 2013-06-12 | — | — | CN | disclosed |
| CN-101970424-A | Indolylpyridone derivatives with checkpoint kinase 1 inhibitory activity | VERNALIS R&D LTD | 2011-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | HSD17B10 3403/4885L3MBTL1 1632/4885POLB 1630/4885 |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | HSD17B10 1060/4885L3MBTL1 806/4885POLB 826/4885 |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | CHEK2, CHEK1, BUB1B | HSD17B10 3403/4885L3MBTL1 1632/4885POLB 1630/4885 |
| US-10399961-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | HSD17B10 857/4885L3MBTL1 1886/4885POLB 4715/4885 |
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | HSD17B10 907/4885L3MBTL1 489/4885POLB 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.